Amgen has exercised an option to acquire the rights to experimental drug CK-1827452 from Cytokinetics.
The drug, which is currently undergoing mid-stage clinical trial, will be used for the treatment of heart failure.
Cytokinetics will receive $50m, and could receive up to $600m in future payments depending on the success of the drug.
Amgen has paid $75m to Cytokinetics for the option to the drug and will exercise the option after examining further results of the clinical trial.
Amgen is focused on the development of medicine for cancer, kidney disease, rheumatoid arthritis and other serious illnesses.